EMALEX BIOSCIENCES - Key Persons
Job Titles:
- Senior Director, Product Development
Job Titles:
- Senior Director of Clinical Operations
David Kim serves as the Senior Director of Clinical Operations at Emalex Biosciences. He is responsible for managing all operational aspects of the clinical development program.
Mr. Kim has over 27 years of experience in the pharmaceutical industry, beginning his career at Abbott Laboratories as a scientist. Previously, he served as Associate Director at Takeda, where he led the Clinical team in submission of New Drug Applications (NDAs). He also served as a Director of Clinical Operations at Baxter, where he led the formation of the Clinical Operations team in their Deerfield, IL and Beltsville, MD offices. He served the last seven years as Director of Project Management and Director of Clinical Trial Management at ICON Clinical Research in rare diseases, anti-infectives and oncology therapeutic areas.
Mr. Kim holds a Bachelor of Science degree from the University of Illinois at Urbana-Champaign.
Doug Frandsen serves as Corporate Controller and is responsible for financial accounting and reporting, budgeting, tax, and financial controls.
Mr. Frandsen brings nearly 20 years of financial expertise to his role at Emalex. Most recently, he served as U.S. Controller for Orphazyme. Prior to that, Mr. Frandsen held various finance and accounting roles of increasing responsibility at Baxter International, Baxalta, Shire Pharmaceuticals, and Takeda Pharmaceuticals over a series of corporate divestitures and acquisitions. He began his career in public accounting at Ernst & Young in Chicago.
Mr. Frandsen holds a Master of Accounting Science degree and a Bachelor of Accounting Science degree from the University of Illinois, Urbana-Champaign.
Eric Messner is CEO at Emalex Biosciences. He is also Senior Vice President of Business Development at Paragon Biosciences, where he identifies opportunities, completes due diligence and integrates new products and companies into the Paragon portfolio.
Mr. Messner has an extensive, successful career in the biopharmaceutical industry. Formerly, he was Vice President of Sales and Marketing for Marathon Pharmaceuticals. Before that, Mr. Messner was CEO of Anagin, and also served as General Manager and Executive Vice President of Sales and Marketing for OPKO Health. Earlier in his career, he was a founder and Vice President of Marketing and Commercial Operations of Proventiv Therapeutics, which was acquired by Cytochroma. At Cytochroma, he was Vice President of Commercial Operations, later Chief Operating Officer and helped lead the sale of Cytochroma to OPKO Health. Mr. Messner also previously held senior marketing roles at Bone Care International and Abbott Laboratories. Mr. Messner earned his MBA from Northwestern University's Kellogg School of Management and his Bachelor of Science in Business Administration from Miami University.
Job Titles:
- Chief Medical Officer, Neurology and
- Chief Medical Officer, Neurology and Senior Vice President, Medical and Scientific Affairs
Dr. Rick Munschauer has extensive academic and industry experience in neurology designing and conducting a host of Phase I-IV clinical trials in multiple neurological therapeutic areas.
Before joining Emalex, he served as vice president of global product development, neurosciences, at PPD, CMO of Marathon and MedDay Pharma, and global head of medical affairs at Biogen.
Prior to his work in the industry, Dr. Munschauer was Smith Professor and Chair, Neurology, University of NY at Buffalo. He has also held multiple professional society leadership roles including the National Board of Directors of the National MS Society, Consortium of MS Centers, and the American Stroke Association.
Dr. Munschauer received bachelor's degrees in Electrical and Mechanical Engineering from Duke University and a master's degree in Mechanical Engineering from MIT. He graduated from McGill University Faculty of Medicine and completed residencies in internal medicine and neurology at Johns Hopkins. Dr. Munschauer also completed fellowships in intensive care at the National Hospital for Nervous Disease, London and neuroimmunology and neuroimaging at the University of NY at Buffalo. He is board certified in neurology, internal medicine and critical care.
Job Titles:
- Vice President, Global Head of Medical and Scientific Affairs
Job Titles:
- Vice President, Chemistry, Manufacturing and Controls ( CMC )
Jay White has over 20 years of experience in pharmaceutical product development, including chemistry, manufacturing and controls, and non-clinical activities. He serves as the Vice President of Chemistry, Manufacturing and Controls, overseeing all aspects of drug substance and drug product research and development.
Previously, Dr. White served as Vice President, Product Development at OPKO Health Inc., Renal Division. Prior to that, he held several positions in increasing responsibility at Cytochroma Inc., including Vice President, Product Development and Vice President, Operations. During his tenure at Cytochroma and OPKO Health, Dr. White oversaw all aspects of the CMC and non-clinical programs for Rayaldee® extended-release capsules, approved by the FDA for treatment of secondary-hyperparathyroidism in Stage 3 & 4 chronic kidney disease patients with vitamin D deficiency.
Dr. White holds a B.Sc. in Biology from McMaster University and earned his Ph.D. in Pathology from Queen's University.
Job Titles:
- Paragon Founder, Chairman and CEO
Jeffrey S. Aronin is a bioscience entrepreneur known for innovating, developing and commercializing a record number of novel neurology medicines that improve the lives of seriously ill patients who have few or no treatments options.
In 2017, Jeff founded Paragon Biosciences, where he is chairman and chief executive officer. Paragon is a global life science leader that creates, builds and funds innovative biology-based companies. It accelerates scientific breakthroughs to solve some of society's most challenging medical problems.
Job Titles:
- Vice President, Regulatory Affairs and Quality Assurance
Job Titles:
- Associate Vice President of Quality Assurance at Emalex
- Associate Vice President, Quality Assurance
With over 18 years of experience in biotechnology, pharmaceutical and medical device industry, Jesse Zapata is the Associate Vice President of Quality Assurance at Emalex.
Mr. Zapata has held various senior management positions in clinical/commercial quality assurance and control for companies in the USA, Mexico and Korea.
He has a Bachelor of Science in Biological Science from DePaul University and advanced studies towards a Master of Science in Regulatory Affairs and Quality Assurance at Temple University.
Job Titles:
- Senior Director of Clinical Operations
Joy Schleyer serves as Senior Director of Clinical Operations at Emalex Biosciences. She is responsible for managing all operational aspects of the clinical pharmacology program.
Ms. Schleyer has over 20 years of experience in the pharmaceutical industry. Previously, she served as Senior Director of Clinical Operations at Skyline Biosciences, a Paragon Biosciences portfolio company. Ms. Schleyer held the positions of Director of Project Management and Director, Clinical Research at Syneos Health where she provided operational guidance and leadership for Phase II-IV programs across multiple therapeutic areas. Prior to her time with Syneos, she coordinated global activity for compound development and international submissions at Takeda Global Research and Development. She began her career monitoring and managing clinical research studies.
Ms. Schleyer holds a Bachelor of Science degree in Biology from St. Cloud State University.
Job Titles:
- Senior Director of Clinical Operations at Emalex
- Senior Director, Clinical Operations
Meredith M. Miller serves as the Senior Director of Clinical Operations at Emalex. She has over 28 years of experience in the pharmaceutical industry and is responsible for managing the operational aspects of the clinical development program.
Previously, Ms. Miller held several positions of increasing responsibility at Abbott Laboratories and Takeda, including Global Program Manager. She later served as an independent Clinical Research Consultant at both Astellas and Takeda where she provided operational guidance and leadership for global Phase II-IV programs primarily in the CNS therapeutic area. Ms. Miller has contributed to the successful clinical program execution and filing of three New Drug Applications, leading to approved pharmaceutical products.
Ms. Miller holds a Bachelor of Science in Biology from Indiana University.
Job Titles:
- Senior Vice President
- Senior Vice President of Legal Affairs and General Counsel
Paul Reinfelds serves as Senior Vice President of Legal Affairs and General Counsel at Emalex Biosciences. He oversees all aspects of corporate and legal matters at Emalex.
Dr. Reinfelds has spent the last 15 years in the pharmaceutical space previously serving as General Counsel at MMB Healthcare and its affiliated companies, Associate General Counsel at Marathon Pharmaceuticals, LLC, Senior Director of U.S. Legal Affairs at Lundbeck Inc., and as Legal Counsel at Ovation Pharmaceuticals. Prior to his legal career, he was a research scientist.
Dr. Reinfelds earned his Ph.D. in Biology from Illinois Institute of Technology, a Juris Doctor from the University of Illinois Chicago School of Law and is a registered patent attorney with the United States Patent and Trademark Office.
Job Titles:
- Vice President, Clinical Development
Sarah Atkinson, M.D., has over 30 years of experience in clinical psychiatry, where she has provided care to patients in a private practice setting, a hospital practice setting, including teaching experience, and in clinical research. She has authored books, chapters of books and numerous papers. Dr. Atkinson has been a guest presenter at many schools, hospitals, associations, and conferences worldwide.
Before joining Emalex, Dr. Atkinson worked for a clinical research organization as a consultant and medical monitor. Previously, she was the director of Finger Lakes Clinical Research where she conducted clinical research for more than 15 years as an investigational site for numerous psychiatric and central nervous system disorders products. Dr. Atkinson has also held numerous positions utilizing her psychiatric expertise at distinguished organizations and health centers.
Dr. Atkinson graduated from the University of Oklahoma College of Medicine. She received a master's degree in mathematics from Tulane University/Princeton University. Dr. Atkinson is board-certified in general psychiatry and child and adolescent psychiatry.
Job Titles:
- Senior Director, Chemistry, Manufacturing and Controls ( CMC ) Regulatory Affairs / Emalex Founder and Chairman
Job Titles:
- Vice President, Biostatistics and Data Management
Trish Rice has more than 25 years of experience as a clinical trial biostatistician. She is the Vice President of Biostatistics and Data Management at Emalex.
Ms. Rice was formerly Vice President of Biostatistics at Jaguar Gene Therapy. Before that she was Executive Director of Biostatistics at Premier Research and served as its global head of biostatistics and SAS programming. In addition, she has held leadership positions at CliniRx USA, Reliance Clinical Research Services and Scirex and began her career at Syntex Research.
Ms. Rice earned her Master of Science in Experimental Statistics from New Mexico State University and her Bachelor of Science in Animal Science from New Mexico State University.